ArticleAmerican journal of cancer research2020

Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models.

Shijing Wang et al.PubMed ↗Full text ↗

No numbers read from the abstract.